



ALGYL CBD: The Future of Targeted Pain Relief.

Next-generation
transdermal efficacy
for clinical and
commercial applications.






The Modern Pain Management Dilemma

THE SYSTEMIC PROBLEM

-  - Gastrointestinal side effects
-  - Unpredictable drug interactions
-  - Significant addiction risks

THE TARGET SOLUTION

-  - Localized, non-invasive application
-  - Prolonged and consistent relief
-  - Zero systemic burden

ALGYL CBD: Precision OTC Medical Device

Regulatory Status

Registered Medical Device (CE Marked), Over-The-Counter (OTC).

Delivery Mechanism

Non-invasive, transdermal application. Thin, flexible, adhesive, and discreet.

Duration


Up to **24-hour** continuous release (**21.7 hours** average).

Indications

Specifically formulated for **musculoskeletal diseases, sports injuries, and arthritis.**



The Tri-Active Synergy System



Purified CBD as a Homeostatic Regulator



Dosage

20mg of purified, isolated, and crystallized CBD per patch for maximum quality.

Action

Interacts directly with CB1/CB2 receptors in the skin.


Effect

Reduces peripheral sensitization (the sensitivity of damaged cells).


Systemic Benefit

Acts as a homeostatic regulator with high potential for autoimmune pain management (e.g., rheumatoid arthritis), entirely avoiding the GI tract.


Mechanism of Action: 24-Hour Transdermal Delivery




Clinical Efficacy: Pain Reduction & Quality of Life




97.50% - Subjects demonstrating **overall Pain Relief**



96.29% - Improvement in **VAS (Visual Analogue Scale) Pain Score**




90.00% - Improvement in **WOMAC (Osteoarthritis) Score**



98.75% - Improvement in **EQ-5D Quality of Life metric**

Clinical Efficacy: Functional Physical Recovery



Clinical data proves the transition from symptom masking to active physical rehabilitation.

Impeccable **Safety & Toxicity Profile**

Zero GI Toxicity

Localized physical/physicochemical action drastically reduces gastrointestinal side effects.



Zero Drug Interactions

Completely safe for polypharmacy patients.



Zero Addiction Potential

Non-habit forming.
Backed by the World Health Organization (WHO).



Zero Adverse Effects

Proven in pre-clinical studies.
100% Vegan formulation.



Global Regulatory Compliance & IP



**Global
Patents
Pending**

CE 

Tested in strict accordance with the European Medical Device Regulation (EU MDR 2017/745).

Fully compliant with MDR Chapter VII, Article 10(9) (Quality Management System) and Article 85.

Pre-clinical and clinical efficacy proven under stringent regulatory standards.

The Independent Zero-THC Guarantee

University of Naples Federico II -
Food Lab Laboratory validation.

**Δ 9-THC & Acid Δ 9-THC:
NF (Not Found)**

**Confirmed CBD Content:
10,000,683.00 ppb**

**Strict non-detectable limits for THC
and all other non-CBD cannabinoids.**

DEPARTAMENTO DE FARMACIA
Df UNIVERSITY OF NAPLES FEDERICO II
Department of Pharmacy
Food Lab Laboratory

Quantitative analysis of CBDA, CBGA, CBG, CBD, CBN, Δ 9-THC and Acid Δ 9-THC through UHPLC Q-Orbitrap HRMS in Cannabis-based galenic preparation

The Food Lab laboratory of the Department of Pharmacy - University of Naples "Federico II", certifies that the quantitative analysis of cannabinoids and metabolites: CBDA, CBGA, CBG, CBD, Δ 9-THC, and acid Δ 9-THC was carried out by ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC Q-Orbitrap HRMS) on the sample (s).

Sample Code	CBDA		CBGA		CBG		CBD	CBN		Δ 9-THC		Δ 9-THC Acid	
	ppb	ng/mL	ppb	ng/mL	ppb	ng/mL		ppb	ng/mL	ppb	ng/mL	ppb	ng/mL
Confecto™ 200 Go Tropic RES125564776 Bott. CL59	<LOQ	<LOQ	NF	NF	NF	NF	10006830	NF	NF	NF	NF	NF	NF

Linearity Range: 5.3.0%

Limit of Quantification (LOQ): 3 ppb

Limit of Detection (LOD): -

Analyst: *[Signature]*
Department of Pharmacy

Food Lab - Department of Pharmacy



Professional Athletics & Synergistic Application



Diagnostic Yes/No Matrix	
WADA Compliant?	YES CBD is the only cannabinoid not on the World Anti-Doping Agency banned list.
Detected in Urine?	NO
Safe with Oral Opioids & Analgesics?	YES
Safe post-Hyaluronic Acid Injections?	YES Pain relief mechanisms act synergistically.



Patient Protocol & Application Guidelines



1. Prepare

Clean and dry skin. Do not apply to broken, irritated, or burned skin.



2. Apply

Apply 1x daily directly to the painful area. Wait minimum 2 hours if other skin products were used.



3. Protect

Do not cover with tight bandages or utilize external heating pads.




4. Renew

Wear for up to 24 hours. For acute pain, consult a doctor if symptoms persist beyond 2-3 days.

The ALGYL Advantage: Proven. Compliant. Ready.

Clinical Efficacy



97.5% proven pain relief via **Tri-Active** synergy of **Menthol, Arnica, and Purified CBD.**

Absolute Safety



Zero THC, absolutely non-addictive, with zero systemic gastrointestinal impact.

Market Readiness



EU MDR Compliant, and **OTC** registered, with **global patents pending.**

Vitafoods 2024 Delegates: Initiate distribution and partnership discussions today